10 June 2020 - NICE has published final guidance backing NHS use of Roche's Kadcyla (trastuzumab emtansine) for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive early breast cancer, that is in people who have already had therapy to shrink their tumour but have residual disease in the breast or surrounding lymph nodes prior to surgery to remove the tumour.

Clinical trial evidence shows that in people who still have some cancer cells remaining after neoadjuvant therapy with a taxane and HER2-targeted treatment, Kadcyla increases the time people remain free of disease compared with Herceptin (trastuzumab) alone, the Institute noted.

Read Pharma Times article